共 50 条
- [21] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches TrialASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33Horvath, LisaArmstrong, Andrew J.Szmulewitz, RussellPetrylak, DanielVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, BorisIguchi, TaroShore, Neal D.Rosbrook, BradSugg, JenniferBaron, BenoitChen, LucyStenzl, Arnulf
- [22] Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancerUROLOGIE, 2023, 62 (04): : 360 - 368Wenzel, MikeHoeh, BenediktChun, Felix K. H.Mandel, Philipp
- [23] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyJOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520Sweeney, C. J.Martin, A. J.Stockler, M. R.Begbie, S.Chi, K. N.Chowdhury, S.Coskinas, X.Frydenberg, M.Hague, W. E.Horvath, L. G.Joshua, A. M.Lawrence, N. J.Marx, G. M.McCaffrey, J.McDermott, R.McJannett, M.North, S. A.Parnis, F.Parulekar, W.Pook, D. W.Reaume, M. N.Sandhu, S. K.Tan, A.Tan, T. H.Thomson, A.Tu, E.Vera-Badillo, F.Williams, S. G.Yip, S.Zhang, A. Y.Zielinski, R. R.Davis, I. D.
- [24] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Editorial CommentJOURNAL OF UROLOGY, 2016, 195 (01): : 94 - 94Taneja, Samir S.
- [25] Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Azad, ArunIguchi, TaroAlekseev, BorisShore, Neal D.Sugg, JenniferHaas, Gabriel P.Wozniak, MicheleO'Brien, ThomasLaird, DouglasStenzl, ArnulfArmstrong, Andrew J.
- [26] Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Szmulewitz, Russell ZeligHolzbeierlein, JeffreyAzad, ArunIguchi, TaroVillers, ArnauldAlcaraz, AntonioAlekseev, BorisShore, Neal D.Rosbrook, BradZohren, FabianMa, JieHaas, Gabriel P.Gomez-Veiga, FranciscoStenzl, ArnulfArmstrong, Andrew J.
- [27] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancerUROLOGIE, 2023, 62 (04): : 354 - 359Boegemann, Martin
- [28] Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical TrialJAMA NETWORK OPEN, 2021, 4 (01) : E2034633Vaishampayan, Ulka N.Heilbrun, Lance K.Monk, Paul, IIITejwani, SheelaSonpavde, GuruHwang, ClaraSmith, DarynJasti, PallaviDobson, KimberleeDickow, BrendaHeath, Elisabeth I.Semaan, LouieCher, Michael L.Fontana, Joseph A.Chinni, Sreenivasa
- [29] Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Armstrong, Andrew J.Szmulewitz, Russell ZeligPetrylak, Daniel PeterVillers, ArnauldAzad, ArunAlcaraz, AntonioAlekseev, Boris Y.Iguchi, TaroShore, Neal D.Rosbrook, BradSugg, JenniferBaron, BenoitChen, Lucy F.Stenzl, Arnulf
- [30] Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc AnalysisEUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 860 - 869Gomez-Veiga, FranciscoSzmulewitz, Russell Z.Holzbeierlein, JeffreyAzad, Arun A.Iguchi, TaroVillers, ArnauldAlcaraz, AntonioAlekseev, BorisShore, Neal D.Rosbrook, BradZohren, FabianMa, JieHaas, Gabriel P.Stenzl, ArnulfArmstrong, Andrew J.